• Home
  • Practice Focus
    • Facial Plastic/Reconstructive
    • Head and Neck
    • Laryngology
    • Otology/Neurotology
    • Pediatric
    • Rhinology
    • Sleep Medicine
    • How I Do It
    • TRIO Best Practices
  • Business of Medicine
    • Health Policy
    • Legal Matters
    • Practice Management
    • Technology
    • AI
  • Literature Reviews
    • Facial Plastic/Reconstructive
    • Head and Neck
    • Laryngology
    • Otology/Neurotology
    • Pediatric
    • Rhinology
    • Sleep Medicine
  • Career
    • Medical Education
    • Professional Development
    • Resident Focus
  • ENT Perspectives
    • ENT Expressions
    • Everyday Ethics
    • From TRIO
    • The Great Debate
    • Letter From the Editor
    • Rx: Wellness
    • The Voice
    • Viewpoint
    • SUO Corner
  • TRIO Resources
    • Triological Society
    • The Laryngoscope
    • Laryngoscope Investigative Otolaryngology
    • TRIO Combined Sections Meetings
    • COSM
    • Related Otolaryngology Events
  • Home
  • Practice Focus
    • Facial Plastic/Reconstructive
    • Head and Neck
    • Laryngology
    • Otology/Neurotology
    • Pediatric
    • Rhinology
    • Sleep Medicine
    • How I Do It
    • TRIO Best Practices
  • Business of Medicine
    • Health Policy
    • Legal Matters
    • Practice Management
    • Technology
    • AI
  • Literature Reviews
    • Facial Plastic/Reconstructive
    • Head and Neck
    • Laryngology
    • Otology/Neurotology
    • Pediatric
    • Rhinology
    • Sleep Medicine
  • Career
    • Medical Education
    • Professional Development
    • Resident Focus
  • ENT Perspectives
    • ENT Expressions
    • Everyday Ethics
    • From TRIO
    • The Great Debate
    • Letter From the Editor
    • Rx: Wellness
    • The Voice
    • Viewpoint
    • SUO Corner
  • TRIO Resources
    • Triological Society
    • The Laryngoscope
    • Laryngoscope Investigative Otolaryngology
    • TRIO Combined Sections Meetings
    • COSM
    • Related Otolaryngology Events
  • Search

Topical Beta-Blocker Effective First-Line Treatment for Infantile Hemangioma

by Linda Kossoff • January 8, 2025

  • Tweet
  • Email a link to a friend (Opens in new window) Email
Print-Friendly Version

CLINICAL QUESTION

How efficient are topical beta-blockers for epistaxis control in a case of ulcerated infantile hemangioma (IH)?

You Might Also Like

  • An Unofficial First-Line Treatment: Propranolol gains widespread use for infantile hemangiomas
  • Can Topical Beta-Blockers Reduce the Size of Superficial Infantile Hemangiomas of the Head and Neck?
  • New Approaches to Vascular Anomalies On the Horizon
  • Hemangioma Treatment not One Size Fits All
Explore This Issue
January 2025

BOTTOM LINE

The topical beta-blocker timolol can be an effective first-line treatment for controlling symptoms of ulcerated IHs; however, its use should be carefully monitored.

BACKGROUND: Infantile hemangiomas are benign, vascular tumors occurring in approximately 4 to 5% of infants. Self-limiting in nature, IHs can still lead to complications such as pain, ulceration, or permanent disfigurement if left untreated. The mainstay and first-line treatment for IHs consists of topical beta-blockers and oral propranolol.

STUDY DESIGN: Case study

SETTING: Otolaryngology–Head and Neck Surgery, University of Florida Health, Gainesville, Fla.

SYNOPSIS: An eight-week-old, full-term, otherwise healthy patient presented with recurrent epistaxis from the right nostril and no concerns for impaired breathing, stridor, or possible compromised airway. Examination revealed an ulcerating hemangioma over the right anterior nasal septum. Continued management with saline spray and Vaseline and a one-month trial of topical timolol 0.5% was recommended. At two weeks, epistaxis had ceased. At four weeks, the hemangioma had improved in appearance but was extending into the oral vestibulum/upper lip and upper jaw. The patient was referred to pediatric cardiology for management of systemic beta-blocker propranolol. Magnetic resonance imaging was ordered to assess the extent of the mass and rule out intracranial abnormalities. At eight weeks, these measures had been taken, but the family subsequently relocated, precluding further follow-up. Researchers note that this case supports the efficacy of topical timolol for controlling symptoms such as bleeding in ulcerated IHs and underscores the importance of close monitoring and the potential need for systemic therapy in cases with limited response to topical treatment. In this case, persistent tumor growth required further intervention, suggesting that more frequent monitoring during the first month of treatment could be helpful.

CITATION: Lam N, Schrepfer T. Efficiency of topical beta-blockers for epistaxis control in ulcerated infantile hemangioma. Cureus. 2024;16(8):e67709. doi: 10.7759/cureus.67709.

Filed Under: Literature Reviews, Pediatric, Pediatric, Pediatric Otolaryngology, Practice Focus Tagged With: infantile hemangiomas, topical beta-blockersIssue: January 2025

You Might Also Like:

  • An Unofficial First-Line Treatment: Propranolol gains widespread use for infantile hemangiomas
  • Can Topical Beta-Blockers Reduce the Size of Superficial Infantile Hemangiomas of the Head and Neck?
  • New Approaches to Vascular Anomalies On the Horizon
  • Hemangioma Treatment not One Size Fits All

The Triological SocietyENTtoday is a publication of The Triological Society.

Polls

More and more medical trainees are taking dedicated, prolonged gap years. Did you?

View Results

Loading ... Loading ...
  • Polls Archive

Top Articles for Residents

  • Is the SLOR in Otolaryngology Residency Applications Contributing to Rural Disparities?
  • Applications Open for Resident Members of the ENTtoday Editorial Board
  • A Resident’s View of AI in Otolaryngology
  • Call for Resident Bowl Questions
  • Resident Pearls: Pediatric Otolaryngologists Share Tips for Safer, Smarter Tonsillectomies
  • Popular this Week
  • Most Popular
  • Most Recent
    • Office Laryngoscopy Is Not Aerosol Generating When Evaluated by Optical Particle Sizer
    • Some Laryngopharyngeal Reflux Resists PPI Treatment
    • Top 10 LARY and LIO Articles of 2024
    • Empty Nose Syndrome: Physiological, Psychological, or Perhaps a Little of Both?
    • Rating Laryngopharyngeal Reflux Severity: How Do Two Common Instruments Compare?
    • The Dramatic Rise in Tongue Tie and Lip Tie Treatment
    • Rating Laryngopharyngeal Reflux Severity: How Do Two Common Instruments Compare?
    • Is Middle Ear Pressure Affected by Continuous Positive Airway Pressure Use?
    • Otolaryngologists Are Still Debating the Effectiveness of Tongue Tie Treatment
    • Keeping Watch for Skin Cancers on the Head and Neck
    • Short-Term Efficacy of Biologics in Recalcitrant AFRS: A Systematic Review and Meta-Analysis
    • The Devaluation of Otolaryngology: An Evaluation of CMS’s Involvement in Physician Reimbursement
    • Embolized Middle Meningeal Artery as a Surgical Landmark in Infratemporal Fossa
    • Lord of the (Magnetic) Rings: Rigid Bronchoscopy for Aspirated Magnetic Foreign Bodies in Tertiary Bronchi
    • What Otolaryngologists Can Learn from Athletes

Follow Us

  • Contact Us
  • About Us
  • Advertise
  • The Triological Society
  • The Laryngoscope
  • Laryngoscope Investigative Otolaryngology
  • Privacy Policy
  • Terms of Use
  • Cookies

Wiley

Copyright © 2026 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1559-4939